NEW YORK (GenomeWeb News) – Roche has received the CE-IVD Mark in Europe for its LightCycler test for methicillin-resistant Staphylococcus aureus allowing it to be sold for clinical use in the EU, the firm said today.

The assay provides direct detection of nasal colonization with MRSA and runs on Roche's LightCycler 2.0 instrument using PCR.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.